Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.

British Journal of Clinical Pharmacology

Volumn 8, Issue 1, 1979, Pages 21-31

  Perucca, E ^a   Richens, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; LIDOCAINE; LORAZEPAM; NORTRIPTYLINE; PARACETAMOL; PERICIAZINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; UNCLASSIFIED DRUG; VALPROIC ACID; XYLOCARP;

ADULT; ADVERSE DRUG REACTION; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG INTERACTION; DRUG METABOLISM; DRUG RESPONSE; EPILEPSY; IMMUNOASSAY; LIVER MICROSOME; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; THERAPY;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; INJECTIONS, INTRAVENOUS; KINETICS; LIDOCAINE; LIVER CIRCULATION; MALE;

EID: 0018356569     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1979.tb05904.x     Document Type: Article

References (54)

1. Lignocaine metabolism in man
2. Impaired absorption and metabolism of oral lignocaine in patients undergoing laparoscopy
3. The effect of atropine on the absorption of lignocaine in man
4. First‐pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma
5. Importance of ‘first‐pass elimination’ for interindividual differences in steady‐state concentrations of the adrenergic beta‐receptor antagonist alprenolol
6. Effect of pentobarbital on the disposition of alprenolol
7. The metabolism and excretion of lignocaine in man
8. Lignocaine pharmacokinetics in man: dose and time studies
9. Lignocaine disposition kinetics in monkey and man: I prediction by a perfusion model
10. Lignocaine disposition kinetics in monkey and man. II effects of haemorrhage and sympathomimetic drug administration
11. A new treatment of status epilepticus. Intravenous injections of a local anaesthetic (lignocaine)
12. The convulsant potency of lignocaine and its N‐dealkylated metabolites
13. Oral absorption and disposition kinetics of lignocaine hydrochloride in dogs
14. Pharmacokinetics of lignocaine in man
15. The reduction of lignocaine clearance by dl‐propranolol: an example of hemodynamic drug interaction
16. Increased clearance of antipyrine and d‐propranolol after phenobarbital treatment in the monkey
17. Lignocaine metabolism in normal and phenobarbital pre‐treated dogs
18. Oral lignocaine
19. Antipyrine, lignocaine and paracetamol metabolism in chronic liver disease
20. Influence of first pass effect on availability of drugs on oral administration
21. Relationship between drug concentration in plasma or serum and amount of drug in the body
22. Influence of congestive heart failure on blood levels of lignocaine and its active monodiethylated metabolite
23. Plasma lignocaine levels in patients treated with potential inducers of microsomal enzymes
24. On the metabolism of lignocaine: ii The biotransformations of lignocaine
25. Plasma levels of lignocaine during combined treatment with phenytoin and procainamide
26. The tissue distribution, metabolism and excretion of lignocaine in rats, guinea pigs, dogs and man
27. Dose‐dependent pharmacokinetics of lignocaine in volunteers
28. The pharmacokinetics of lignocaine after prolonged intravenous infusions in man
29. Effect of the duration of infusion on the disposition of lignocaine in dogs
30. Effect of diphenylhydantoin on the metabolism of metyrapone and release of ACTH in man
31. Lignocaine kinetics in cardiac patients and aged subjects
32. Changes in liver blood flow during enzyme induction
33. Oral lignocaine: its absorption and effectiveness in ventricular arrhythmia control
34. Clearance and biologic half‐life as indices of intrinsic hepatic metabolism
35. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs
36. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance
37. Liver enzyme induction by antiepileptic drugs, its clinical significance
38. The relationship between liver volume, antipyrine clearance, and indocyanine green clearance before and after phenobarbital administration in man
39. Influence of route of administration on drug availability
40. Clearance concepts in pharmacokinetics
41. Disposition kinetics of lignocaine in normal subjects
42. Antiarrhythmic drugs: electro‐physiological and pharmacokinetic considerations
43. Interrelationship of hepatic blood flow, cardiac output, and blood levels of lignocaine in man
44. Identification of glycine xylidide in patients treated with intravenous lignocaine
45. Lignocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans
46. Pharmacokinetics of local anaesthetic agents
47. On the ‘first‐pass’ effect in the liver of nortriptyline, lignocaine and propranolol
48. Human hepatic blood flow and its relation to systemic circulation during intravenous infusion of lignocaine
49. Pharmacokinetics of drug disposition: haemodynamic considerations
50. A physiological approach to hepatic drug clearance
51. Bioavailability of lignocaine in normal volunteers and cirrhotic patients